SCIENCE IN THE NEWS DAILY
Testing a Drug That May Stop Alzheimer's Before It Starts
from the New York Times (Registration Required)
In a clinical trial that could lead to treatments that prevent Alzheimer's disease, people who are genetically guaranteed to suffer from the disease years from now--but who do not yet have any symptoms--will for the first time be given a drug intended to stop them from developing it, federal officials announced Tuesday.
Experts say the study will be one of only a very few ever conducted to test prevention treatments for any genetically predestined disease. In Alzheimer's research, the trial is unprecedented, "the first to focus on people who are cognitively normal but at very high risk for Alzheimer's disease," said Dr. Francis S. Collins, director of the National Institutes of Health. Most of the study's participants will be drawn from an extended family of 5,000 people who live in Medellín, Colombia, and remote mountain villages outside that city.
The family is believed to have more members who suffer from Alzheimer's than any other in the world. Those who possess a specific genetic mutation begin showing cognitive impairment around age 45, and full-blown dementia around age 51. The 300 family members who participate in the initial phase of the trial will be years away from developing symptoms. Some will be as young as 30.
Connect With Us:
PODCASTS: Expanding With the Cosmos
Using the Atacama Cosmology Telescope (ATC), a 6.5-meter microwave collector in Chile, cosmologists are piecing together the early history of the known universe. In an exclusive American Scientist interview, Arthur Kosowsky—a member of the ATC team and a professor in the Department of Physics and Astronomy at the University of Pittsburgh—discusses how he is using ATC to reach back in time billions of years to search for gravitational waves that could verify inflation and reveal unprecedented details about how the cosmos was born.
To view all multimedia content, click "Latest Multimedia."
Receive notification when new content is posted from the entire website, or choose from the customized feeds available.